Answers are grounded in this paper and cite their sources.
To facilitate containment of the COVID-19 pandemic currently active in the United States and across the world, options for easy, non-invasive antibody testing are required. Here we have adapted a commercially available, serum-based enzyme-linked immunosorbent assay (ELISA) for use with saliva samples, achieving 84.2% sensitivity and 100% specificity in a set of 149 clinical samples. This strategy will enable widespread, affordable testing for patients who experienced this disease, whilst minimizing exposure risk for healthcare workers.
No takes yet. Share an insight, caveat, or question.
MacMullan et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: